MARKET OUTLOOK

Although TNF-alpha inhibitors remain the preferred choice for psoriatic arthritis (PsA) treatment following conventional DMARDs, the more recently introduced IL-17 inhibitors, Cosentyx and Taltz, and the oral therapies Otezla and Xeljanz have chipped away at the TNF inhibitors’ patient share. Understanding the unmet need in the treatment of PsA and the factors that can differentiate similar products from one another can determine the success of an agent in this competitive space. This report discusses the unmet needs associated with PsA treatment, based on the perceptions of U.S. and European rheumatologists, and which emerging therapies, if any, can capitalize on these opportunities.

QUESTIONS ANSWERED

  • How do Novartis’s Cosentyx, Celgene’s Otezla, and Pfizer’s Xeljanz compare with the other agents used to treat PsA in terms of efficacy, safety, convenience of administration, and access to reimbursement?
  • How do ACR response, PASI score, HAQ-DI improvement, risk of malignancy, and rate of infection affect rheumatologists’ prescribing decisions individually?
  • How do U.S. and European rheumatologists view the value of oral therapies in treating PsA?
  • What are the prevailing areas of unmet need and opportunity in the PsA therapy market?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European rheumatologists fielded in February 2019

Key companies: AbbVie, Amgen, Janssen, Celgene, Novartis, Pfizer

Key drugs: Adalimumab, etanercept, infliximab, ustekinumab, apremilast, secukinumab, tofacitinib

Table of contents

  • Detailed, Expanded Analysis (US & EU)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
        • Nonclinical Factors
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in PsA
      • Key Findings: Unmet Need in PsA and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the PsA Market and Emerging Therapy Insights
        • Opportunity: A More-Efficacious Oral Targeted Synthetic DMARD
        • Opportunity: A Biologic That Is More Efficacious than TNF-Alpha Inhibitors in Treating PsA-Associated Musculoskeletal Disease
        • Opportunity: A New Biologic with Longer Sustained Efficacy
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • PsA Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix
      • Experts Interviewed
      • Bibliography

Author(s): Yingdee Unhavaithaya

Yingdee Unhavaithaya is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, primarily focusing on psoriasis. Prior to joining DRG, Yingdee was an analyst at Citeline, where he analyzed data on oncology clinical trials ; He was also a business development intern at the Massachusetts General Hospital Research Ventures and Licensing office, where he performed market research to look for invention licensing ; Yingdee received his in cell biology from the University of Massachusetts Medical School, and a in biology from the University of Pittsburgh at Greensburg.


Related Reports

Psoriatic Arthritis | Landscape & Forecast | Disease Landscape & Forecast

PsA, a disease characterized by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underd...

View Details

Psoriatic Arthritis | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Market Outlook: Psoriatic arthritis (PsA) treatment typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics or targeted...

View Details

Psoriatic Arthritis | Emerging Therapies | Xeljanz (tofacitinib) Psoriatic Arthritis - Wave 3 (US)

Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA) and the only other oral targeted ther...

View Details

Psoriatic Arthritis | Disease Landscape and Forecast | G7 | 2018

PsA, a disease characterized by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly un...

View Details